Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Hemorheol Microcirc ; 24(2): 93-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11381184

RESUMO

Fifteen cases of endometrial cancer were administered daily doses of 600 mg of MPA after surgery to prevent the recurrence of cancer. The initiation times of coagulation (time necessary for fibrin network formation) were measured with a highly sensitive damped oscillation rheometer and compared with those of 15 control patients who were not administered MPA. Biochemical studies of blood coagulation and fibrinolysis were also done. The initiation times of coagulation were 19.0+/-1.8 minutes (min mean +/- standard deviation) after 3-6 months and 16.0+/-2.0 min after 9-12 months of MPA administration, both times being significantly shorter compared with the controls (24.0+/-2.5 min). Hematocrit values, platelet counts and fibrinogen levels were similar between the two groups. Activated partial thromboplastin time (APTT) was significantly decreased and antithrombin III activity (AT III), thrombin-antithrombin complex (TAT), plasminogen level, plasmin-alpha(2) plasmin inhibitor complex level (PIC) and the fibrin degradation product level (FDP) were significantly increased in the MPA group compared with the control group. Accelerated coagulation of blood was definitely induced by high-dose MPA but antithrombin and fibrinolytic activities were also induced, and, thus, thromboembolic complications were prevented.


Assuntos
Antifibrinolíticos , Antineoplásicos Hormonais/farmacologia , Neoplasias do Endométrio/sangue , Hemostasia/efeitos dos fármacos , Acetato de Medroxiprogesterona/farmacologia , Adulto , Idoso , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Hormonais/efeitos adversos , Antineoplásicos Hormonais/uso terapêutico , Antitrombina III/análise , Coagulação Sanguínea/efeitos dos fármacos , Testes de Coagulação Sanguínea , Viscosidade Sanguínea , Terapia Combinada , Neoplasias do Endométrio/tratamento farmacológico , Neoplasias do Endométrio/cirurgia , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinogênio/análise , Fibrinolisina/análise , Fibrinólise/efeitos dos fármacos , Hematócrito , Humanos , Histerectomia , Acetato de Medroxiprogesterona/administração & dosagem , Acetato de Medroxiprogesterona/efeitos adversos , Acetato de Medroxiprogesterona/uso terapêutico , Pessoa de Meia-Idade , Tempo de Tromboplastina Parcial , Peptídeo Hidrolases/análise , Contagem de Plaquetas , Risco , Trombofilia/induzido quimicamente , Trombofilia/epidemiologia , alfa 2-Antiplasmina/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...